摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-溴喹啉-6-羧酸 | 219763-87-8

中文名称
4-溴喹啉-6-羧酸
中文别名
——
英文名称
4-bromoquinoline-6-carboxylic acid
英文别名
——
4-溴喹啉-6-羧酸化学式
CAS
219763-87-8
化学式
C10H6BrNO2
mdl
——
分子量
252.067
InChiKey
LXDXJSHQARTINV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    403.1±30.0 °C(Predicted)
  • 密度:
    1.732±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    50.2
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933499090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:97f6cdf6c6faf7838d608fab362c04d1
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Bromoquinoline-6-carboxylic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromoquinoline-6-carboxylic acid
CAS number: 219763-87-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H6BrNO2
Molecular weight: 252.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

概述

4-溴喹啉-6-羧酸是一种羧酸类衍生物,可用作医药合成中间体。

应急措施
  • 若吸入4-溴喹啉-6-羧酸,请将患者移至空气新鲜处。
  • 如皮肤接触,应脱去污染衣物,并用肥皂水和清水彻底清洗皮肤;如有不适,请就医。
  • 若眼睛接触,需分开眼睑,用流动清水或生理盐水冲洗,并立即就医。
  • 如误食,请立即漱口,禁止催吐,并尽快就医。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-溴喹啉-6-羧酸2-双环己基膦-2',6'-二甲氧基联苯potassium phosphate monohydrate 、 palladium diacetate 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 生成 (E)-N-methoxy-N-methyl-4-styrylquinoline-6-carboxamide
    参考文献:
    名称:
    QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    摘要:
    本发明涉及喹啉衍生物,含有该衍生物的药物组合物以及它们在治疗由CB-1受体介导的疾病和症状中的应用;更具体地,在对CB-1受体的反向拮抗作用响应的疾病和症状的治疗中。例如,本发明的化合物在治疗代谢性疾病方面是有用的。
    公开号:
    US20150239845A1
  • 作为产物:
    描述:
    4-甲氧基喹啉-6-羧酸甲酯sodium hydroxide三溴化磷 作用下, 以 四氢呋喃甲醇 、 DMF (N,N-dimethyl-formamide) 、 为溶剂, 反应 8.0h, 生成 4-溴喹啉-6-羧酸
    参考文献:
    名称:
    Sulfonamide compounds and medicinal use thereof
    摘要:
    化合物的化学式(I)为磺胺类化合物: R1—SO2NHCO—A—R2  (I) 其中R1为烷基,烯基,炔基等;A为除苯并咪唑基,吲哚基,4,7-二氢苯并咪唑基和2,3-二氢苯并噁嗪基之外的可选择取代的杂多环基团;X为烷基,氧杂环烷基等;R2为可选择取代的芳基,取代的联苯基等,其盐及包含其的药物组合物。该磺胺类化合物对于基于其降低血糖水平活性、cGMP-PDE(特别是PDE-V)抑制活性、平滑肌松弛活性、支气管扩张活性、血管扩张活性、平滑肌细胞抑制活性和抗过敏活性可治疗的疾病有效。
    公开号:
    US06348474B1
点击查看最新优质反应信息

文献信息

  • AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME
    申请人:Shishido Yuji
    公开号:US20120088746A1
    公开(公告)日:2012-04-12
    Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
    披露了具有以下公式表示的化合物:公式(I)。这些化合物可以制备为药物组合物,并可用于预防和治疗包括人类在内的哺乳动物的各种疾病,例如疼痛、炎症、创伤性损伤等。
  • Monoacylglycerol Lipase Modulators
    申请人:Janssen Pharmaceutica NV
    公开号:US20200102303A1
    公开(公告)日:2020-04-02
    Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.
    化合物的结构式(I)和结构式(II),含有它们的药物组合物,制备它们的方法,以及使用它们的方法,包括用于治疗与MGL调节相关的疾病状态、紊乱和病况的方法,例如与疼痛、精神障碍、神经障碍(包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症)、癌症和眼部疾病相关的方法。 其中R1、R2、R2a、R3、R3a、R4和R4a在此处定义。
  • [EN] PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS<br/>[FR] DÉRIVÉS D'AMINO PYRIDAZINYLE UTILISÉS EN TANT QU'INHIBITEURS D'ALK5
    申请人:CHIESI FARM SPA
    公开号:WO2022013307A1
    公开(公告)日:2022-01-20
    The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    本发明涉及一种通式(I)的化合物,抑制转化生长因子-β(TGF-β)类型I受体(ALK5),制备这种化合物的方法,包含它们的药物组合物以及它们的治疗用途。本发明的化合物可能对哺乳动物中ALK5信号通路失调相关的疾病或病症的治疗有用。
  • Sulfonamide compounds and pharmaceutical use thereof
    申请人:Fujisawa Pharmaceutical Co. Ltd.
    公开号:US20020099212A1
    公开(公告)日:2002-07-25
    A sulfonamide compound of the formula (I): R 1 —SO 2 NHCO—A—X—R 2 (I) wherein R 1 is alky, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.
    化合物I的磺酰胺类化合物:R1-SO2NHCO-A-X-R2(I),其中R1是烷基,烯基,炔基等;A是可选取代的异杂多环基团,但不包括苯并咪唑基,吲哚基,4,7-二氢苯并咪唑基和2,3-二氢苯并噁唑基;X是烷基,氧杂环烷基,氧杂环(低)烷基等;R2是可选取代的芳基,取代联苯基等,其盐和药物组成物。该磺酰胺类化合物对于可基于其降低血糖水平的活性、cGMP-PDE(特别是PDE-V)抑制活性、平滑肌松弛活性、支气管扩张活性、血管扩张活性、平滑肌细胞抑制活性和抗过敏活性可治疗的疾病有效。
  • Quinoline derivatives useful as CB-1 inverse agonists
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:US09266835B2
    公开(公告)日:2016-02-23
    The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
    本发明涉及喹啉衍生物、含有该衍生物的药物组合物及其在治疗由CB-1受体介导的疾病和症状中的应用;更具体地,在治疗对CB-1受体的反向激动作用有响应的疾病和症状中的应用。例如,本发明的化合物在治疗代谢性疾病方面是有用的。
查看更多